Published in Hepatitis Weekly, January 16th, 2006
Results showed superiority of Heplisav compared to Engerix-B relative to the primary efficacy endpoint of seroprotection (100% seroprotection in the Heplisav-treated group compared to 90.5% in the Engerix-B treated group; and relative to geometric mean concentration or GMC (1698 compared to 569 mIU/mL. Results also showed that subjects treated with Heplisav experienced more durable seroprotection. At week 50, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.